Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 650-kidney-transplant-with-hemodialysis-with-mcc
    Ask Trek AI about this page

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    DRG 650 addresses kidney transplantation cases that require hemodialysis and include at least one Major Complication or Comorbidity, reflecting higher clinical complexity and resource needs. Correct classification into this Diagnosis-Related Group is important for appropriate inpatient reimbursement under Medicare payment policies.

    Customize your policy alerts

    Sign up for drg 650 policy alerts

    Get alerted when payer policies referencing 650 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 650 Overview

    DRG 650 covers inpatient hospitalizations for kidney transplantation where the patient receives hemodialysis and has at least one Major Complication or Comorbidity. This Diagnosis-Related Group applies when the clinical complexity of postoperative care and renal replacement therapy increases resource use and length of stay. It matters for Medicare payment because the presence of Major Complication or Comorbidity alters relative weight and reimbursement under the inpatient prospective payment system. Accurate coding of procedures and comorbid conditions determines classification into this higher-severity group.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Studies evaluating perioperative dialysis strategies and timing for kidney transplant recipients who require hemodialysis: randomized or prospective cohort studies compare different approaches to intraoperative and immediate postoperative dialysis (such as timing of first post-transplant dialysis session, modality adjustments, and dialysis intensity) in patients with end-stage renal disease receiving a kidney transplant and who experience delayed graft function or fluid/electrolyte disturbances. These trials focus on the early inpatient period and critically ill transplant recipients with major complications (the MCC group) to determine protocols that optimize graft perfusion, reduce metabolic derangements, and shorten ICU/hospital length of stay; results are highly relevant to clinicians and hospital payers because dialysis timing and frequency directly affect resource use, complication rates, and reimbursement for high-acuity transplant admissions.
    • Comparative effectiveness research on immunosuppression regimens and infection risk in high-risk transplant recipients: observational cohorts and pragmatic trials compare different induction and maintenance immunosuppression strategies, dosing adjustments, or monitoring protocols specifically among patients with significant comorbidities or post-transplant complications requiring hemodialysis. These studies address the balance between preventing rejection and minimizing serious infections or other adverse events in the complex MCC population, informing inpatient management pathways, readmission risk mitigation, and payer considerations around drug utilization and downstream costs related to complications.
    • Post-discharge outcomes and care transitions studies focusing on readmission reduction and graft survival in patients with delayed graft function who needed inpatient hemodialysis: prospective registry analyses and quality-improvement trials test bundled care pathways, early outpatient dialysis coordination, and enhanced monitoring programs for the high-risk subgroup discharged after a transplant admission complicated by hemodialysis. By targeting predictors of early readmission, graft loss, and prolonged post-transplant dialysis dependence, this research helps providers design discharge plans and helps payers evaluate interventions that could lower costly readmissions and improve long-term transplant outcomes.

    Related Codes

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.